Nuclear Medicine News and Research

RSS

Nuclear medicine is a branch or specialty of medicine and medical imaging that uses radioactive isotopes (radionuclides) and relies on the process of radioactive decay in the diagnosis and treatment of disease. In nuclear medicine procedures, radionuclides are combined with other chemical compounds or pharmaceuticals to form radiopharmaceuticals.

Toshiba receives FDA approval for new MR software upgrade

To streamline diagnosis and enable greater overall exam efficiency, Toshiba America Medical Systems, Inc. has announced FDA approval of VirtualExplorer Version 3.1, a software upgrade package for Toshiba MR VirtualExplorer workstations.

11 Jul 2011

Self-referral physicians may contribute to diagnostic imaging growth

A recent study in the Journal of the American College of Radiology suggests that self-referral in medical imaging may be a significant contributing factor in diagnostic imaging growth.

2 Jul 2011

Integrating clinical decision support into PACS improves tool usage among radiologists

Integration with a picture archiving and communication system (PACS) improves radiologists' use of clinical decision support tools, according to a study in the July issue of the Journal of the American College of Radiology.

1 Jul 2011

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of the first of two Phase 3 clinical trials to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD).

1 Jul 2011

Molecular radiotherapy offers hope for children with neuroblastoma

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine.

30 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

Federal Ministry of Health supports radionuclide production at Research Neutron Source

The German Federal Ministry of Health has awarded more than one million euros in research and development funding for the efficient production of an important cancer diagnostic agent at the research neutron source FRM II. In a 2009 feasibility study, the Technische Universitaet Muenchen demonstrated that due to the high neutron flux the neutron source in Garching can produce about half of the European demand of the radioisotope molybdenum-99.

28 Jun 2011

ACS to honor Brookhaven Lab's senior chemist for brain research

Joanna Fowler, a senior chemist and director of radiotracer chemistry, instrumentation, and biological imaging at the U.S. Department of Energy's Brookhaven National Laboratory, is one of 23 women from around the world who has been chosen to receive a Distinguished Women in Chemistry/Chemical Engineering Award, sponsored by the American Chemical Society (ACS).

27 Jun 2011

CPDC, UHN to advance use of medical isotopes for cancer treatment and diagnosis

CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development and Commercialization (CPDC) and the University Health Network.

23 Jun 2011

CoreLab Partners' new technological solutions to be showcased at DIA 2011

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, will showcase several new technological solutions to coincide with the upcoming DIA meeting in Chicago, Illinois to be held from June 20 - 23, 2011.

17 Jun 2011

New weapon in the fight against cancer

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system.

17 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.

8 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

GE Healthcare to highlight advanced portfolio of molecular imaging technologies at SNM meeting

Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio.

4 Jun 2011

Battelle, Perma-Fix sign exclusive option agreement to make medical isotopes

Perma-Fix Environmental Services, Inc. today announced it has signed an exclusive option agreement with Battelle, which operates Pacific Northwest National Laboratory for the U.S. Department of Energy, to license technology from PNNL for use with Perma-Fix's proprietary process to safely and cost-effectively produce Molybdenum-99 (Mo-99), which is used to make Technetium 99m (Tc-99m).

4 Jun 2011

Dilon Diagnostics to introduce latest advancement in molecular breast imaging at SNM meeting

Dilon Diagnostics will introduce the latest advancement in molecular breast imaging (MBI) this week at the Society of Nuclear Medicine (SNM) Meeting in San Antonio, Texas, with the premiere of its FDA-cleared Dilon 6800® Acella Gamma Camera system.

3 Jun 2011

PET scans can help determine patients' response to treatment for HIV-MDR tuberculosis

With the deficiencies in knowledge of tuberculosis-as well as in the practices, programs and strategies used to combat the disease and co-infection with human immunodeficiency virus-the spread of multidrug-resistant tuberculosis poses a major problem for the health care community.

25 May 2011

Asymptomatic patients do not benefit from CT angiography screening

Coronary computed tomographic angiography, which can detect plaque buildup in heart vessels, is sometimes used as a screening tool to assess the risk for a heart attack. However, the usefulness of the test on low-risk patients who do not have coronary symptoms, such as chest pain, has been unclear.

24 May 2011

OctreoPharm Sciences granted SME status by the EMA

OctreoPharm Sciences GmbH, a medicine developer and specialist for radioactive labeled contrast agents in nuclear medicine has been granted SME status as small-sized enterprise in research and development by the European Medicine Agency EMA.

18 May 2011